Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group

BACKGROUND: Pazopanib is a tyrosine kinase inhibitor with antiangiogenic activity. Vascular endothelial growth factor expression is increased in SCLC and is correlated with poor prognosis. The efficacy and tolerance of second-line pazopanib in SCLC was evaluated. PATIENTS AND METHODS: Patients with...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Cancer
Main Authors: Koinis, F, Agelaki, S, Karavassilis, V, Kentepozidis, N, Samantas, E, Peroukidis, S, Katsaounis, P, Hartabilas, E, Varthalitis, I I, Messaritakis, I, Fountzilas, G, Georgoulias, V, Kotsakis, A
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2017
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5520202/
https://ncbi.nlm.nih.gov/pubmed/28510571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.137
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki